Authors: Jade Parker, Editor
We recently caught up with Arndt Vogel from Hanover Medical University (Germany) to learn about clinically meaningful data from a pivotal Phase III study which indicates that lenvatinib is non-inferior to sorafenib in median overall survival for the first line systemic treatment of patients with unresectable hepatocellular carcinoma (HCC). In this interview you can find out about the current treatment options for unresectable HCC, the design and results of the REFLECT trial and the clinical significance of its findings.
What are the current treatment options for unresectable HCC?
- The rate of liver cancer has been rising steadily over the past decade and mortality rates remain high. More than 70% of patients who have advanced disease at the time of diagnosis are not candidates for curative treatment modalities such as surgery. Patients with intermediate disease can, in most cases, be initially treated with local therapies such as transcatheter arterial chemoembolization (TACE). Patients not responding to TACE or with extra hepatic disease require systemic therapy.
- At present, there is only one systemic therapy (sorafenib) approved by the European Medicines Agency for the first-line treatment of unresectable HCC and the median survival for patients is only 1 year. Patients are therefore in real need of additional treatment options.